Journal article
The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32–35 weeks: a Canadian-based analysis*
Abstract
BACKGROUND: Prophylactic therapy with palivizumab, a humanized monoclonal antibody, has been shown to reduce the number of respiratory syncytial virus (RSV)-related hospitalizations in preterm infants, including those in the 32-35 weeks' gestational age (GA) subgroup. The cost-effectiveness of this therapy in Canada is unknown.
OBJECTIVES: To evaluate the cost-effectiveness of palivizumab as respiratory syncytial virus prophylaxis in premature …
Authors
Lanctôt KL; Masoud ST; Paes BA; Tarride J-E; Chiu A; Hui C; Francis PL; Oh PI
Journal
Current Medical Research and Opinion, Vol. 24, No. 11, pp. 3223–3237
Publisher
Taylor & Francis
Publication Date
November 2008
DOI
10.1185/03007990802484234
ISSN
0300-7995
Associated Experts
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
AlgorithmsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntiviral AgentsCanadaChemopreventionCost-Benefit AnalysisDecision Support TechniquesDecision TreesFemaleGestational AgeHealth Care CostsHumansInfant, NewbornInfant, PrematureInfant, Premature, DiseasesIntensive Care Units, NeonatalLength of StayMalePalivizumabRespiratory Syncytial Virus Infections